# Summary statistics - qualitative results

(Groups: measurement principle)

## EQA round: RF1/22 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 18.03.2022

Key: >>> ... marks correct (expected) result
> ... marks conditionally correct (acceptable) result
± ... marks the result not evaluated
N ... number of the results
Nrel ... relative number of the results

| Test Sample | Group | | N | Result | $N_{rel}$ |
|---|---|---|---|---|---|
| **Set 1** | | | | | |
| **(231) Rheumat. fac. (scr)** | | | | | |
| A1 | (2) EIA methods | >>> | 2 | Positive | 1,2 % |
| | (3) IMT, IMN | | 2 | Negative | 1,2 % |
| | | >>> | 164 | Positive | 96 % |
| | (7) Semi-quan. aglut. m. | >>> | 2 | Positive | 1,2 % |
| | Total per sample: n = 170 - Success: 99 % | | | | |
| B1 | (2) EIA methods | >>> | 2 | Negative | 1,2 % |
| | (3) IMT, IMN | >>> | 166 | Negative | 98 % |
| | (7) Semi-quan. aglut. m. | >>> | 2 | Negative | 1,2 % |
| | Total per sample: n = 170 - Success: 100 % | | | | |
| Total success: 99 % | | | | | |
| **(233) Rheumat. factor IgG** | | | | | |
| A1 | (0) Not specified | | 1 | Negative | 2,1 % |
| | | | 1 | Inconclusive result (borderline) | 2,1 % |
| | | >>> | 46 | Positive | 96 % |
| | Total per sample: n = 48 - Success: 96 % | | | | |
| B1 | (0) Not specified | >>> | 48 | Negative | 100 % |
| | Total per sample: n = 48 - Success: 100 % | | | | |
| Total success: 96 % | | | | | |
| **(234) Rheumat. factor IgA** | | | | | |
| A1 | (0) Not specified | | 1 | Inconclusive result (borderline) | 2,2 % |
| | | >>> | 45 | Positive | 98 % |
| | Total per sample: n = 46 - Success: 98 % | | | | |
| B1 | (0) Not specified | >>> | 46 | Negative | 100 % |
| | Total per sample: n = 46 - Success: 100 % | | | | |
| Total success: 98 % | | | | | |
| **(235) Rheumat. factor IgM** | | | | | |
| A1 | (0) Not specified | >>> | 46 | Positive | 100 % |
| | Total per sample: n = 46 - Success: 100 % | | | | |
| B1 | (0) Not specified | >>> | 45 | Negative | 98 % |
| | | | 1 | Positive | 2,2 % |
| | Total per sample: n = 46 - Success: 98 % | | | | |
| Total success: 98 % | | | | | |
| **(277) anti-CCP IgG** | | | | | |
| A1 | (2) EIA (ELISA) | >>> | 34 | Positive | 40 % |
| | (3) FIA (FEIA, TRACE) | >>> | 3 | Positive | 3,6 % |
| | (4) LIA (CLIA, CMIA, ECLIA, LOCI) | >>> | 47 | Positive | 56 % |
| | Total per sample: n = 84 - Success: 100 % | | | | |
| B1 | (2) EIA (ELISA) | >>> | 34 | Negative | 40 % |
| | (3) FIA (FEIA, TRACE) | >>> | 3 | Negative | 3,6 % |
| | (4) LIA (CLIA, CMIA, ECLIA, LOCI) | >>> | 47 | Negative | 56 % |
| | Total per sample: n = 84 - Success: 100 % | | | | |
| Total success: 100 % | | | | | |
| **(282) anti-MCV** | | | | | |
| A1 | (2) EIA (ELISA) | >>> | 22 | Positive | 96 % |
| | (3) FIA (FEIA, TRACE) | >>> | 1 | Positive | 4,3 % |
| | Total per sample: n = 23 - Success: 100 % | | | | |
| B1 | (2) EIA (ELISA) | >>> | 22 | Negative | 96 % |
| | (3) FIA (FEIA, TRACE) | >>> | 1 | Negative | 4,3 % |
| | Total per sample: n = 23 - Success: 100 % | | | | |
| Total success: 100 % | | | | | |